A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This study is a single center, prospective exploratory pilot study of Sickle Cell Anemia
(SCA) participants. The study will enroll patients with early stages of sickle cell
nephropathy (Chronic Kidney Disease (CKD) stage 1 or 2) who are at the highest risk of CKD
progression (presence of both hemoglobinuria and urine albumin concentration ≥ 30 mg/g
creatinin